These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 33477089

  • 21. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P, Montagner D, Ang WH.
    ChemMedChem; 2018 Jun 20; 13(12):1210-1217. PubMed ID: 29637702
    [Abstract] [Full Text] [Related]

  • 22. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M, Hartinger CG.
    Future Med Chem; 2018 Mar 01; 10(6):615-617. PubMed ID: 29411994
    [Abstract] [Full Text] [Related]

  • 23. An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.
    Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V.
    Chemistry; 2019 Apr 05; 25(20):5235-5245. PubMed ID: 30740808
    [Abstract] [Full Text] [Related]

  • 24. A safe and efficacious Pt(ii) anticancer prodrug: design, synthesis, in vitro efficacy, the role of carrier ligands and in vivo tumour growth inhibition.
    Dutta PK, Sharma R, Kumari S, Dubey RD, Sarkar S, Paulraj J, Vijaykumar G, Pandey M, Sravanti L, Samarla M, Das HS, Yashpal, B H, Goyal R, Gupta N, Mandal SK, Sengupta A, Sarkar A.
    Chem Commun (Camb); 2019 Feb 05; 55(12):1718-1721. PubMed ID: 30623966
    [Abstract] [Full Text] [Related]

  • 25. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
    Gibson D.
    ChemMedChem; 2021 Jul 20; 16(14):2188-2191. PubMed ID: 33928760
    [Abstract] [Full Text] [Related]

  • 26. Fluorogenic platinum(IV) complexes as potential predictors for the design of hypoxia-activated platinum(IV) prodrugs.
    Marsh JW, Hacker L, Huang S, Boulet MHC, White JRG, Martin LAW, Yeomans MA, Han HH, Diez-Perez I, Musgrave RA, Hammond EM, Sedgwick AC.
    Dalton Trans; 2024 Sep 10; 53(35):14811-14816. PubMed ID: 39169877
    [Abstract] [Full Text] [Related]

  • 27. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
    Ma L, Ma R, Wang Z, Yiu SM, Zhu G.
    Chem Commun (Camb); 2016 Sep 14; 52(71):10735-8. PubMed ID: 27506281
    [Abstract] [Full Text] [Related]

  • 28. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z, Hu W, Wang Z, Gou S.
    Eur J Med Chem; 2017 Dec 01; 141():211-220. PubMed ID: 29031068
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors.
    Cao Q, Zhou DJ, Pan ZY, Yang GG, Zhang H, Ji LN, Mao ZW.
    Angew Chem Int Ed Engl; 2020 Oct 12; 59(42):18556-18562. PubMed ID: 32557982
    [Abstract] [Full Text] [Related]

  • 36. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
    Wang X, Li L, Pei S, Zhu Q, Chen F.
    Pharmazie; 2020 Mar 20; 75(2):94-101. PubMed ID: 32213241
    [Abstract] [Full Text] [Related]

  • 37. A Multi-action PtIV Conjugate with Oleate and Cinnamate Ligands Targets Human Epithelial Growth Factor Receptor HER2 in Aggressive Breast Cancer Cells.
    Kostrhunova H, Zajac J, Markova L, Brabec V, Kasparkova J.
    Angew Chem Int Ed Engl; 2020 Nov 16; 59(47):21157-21162. PubMed ID: 32750194
    [Abstract] [Full Text] [Related]

  • 38. A red-light activatable and mitochondrion-targeting PtIV complex to overcome drug resistance.
    Li Y, Wang Z, Qi Y, Tang Z, Li X, Huang Y.
    Chem Commun (Camb); 2022 Jul 26; 58(60):8404-8407. PubMed ID: 35796077
    [Abstract] [Full Text] [Related]

  • 39. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
    Novohradsky V, Zerzankova L, Stepankova J, Vrana O, Raveendran R, Gibson D, Kasparkova J, Brabec V.
    J Inorg Biochem; 2014 Nov 26; 140():72-9. PubMed ID: 25063910
    [Abstract] [Full Text] [Related]

  • 40. NIR Light and GSH Dual-Responsive Upconversion Nanoparticles Loaded with Multifunctional Platinum(IV) Prodrug and RGD Peptide for Precise Cancer Therapy.
    Liu XM, Zhu ZZ, He XR, Zou YH, Chen Q, Wang XY, Liu HM, Qiao X, Wang X, Xu JY.
    ACS Appl Mater Interfaces; 2024 Aug 07; 16(31):40753-40766. PubMed ID: 39046129
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.